ADC
-
8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
-
Gilead | A Ray of Hope for the Highly Anticipated TROP2 ADC Trodelvy
DrugTimes team will follow up on this hot field and report timely. Please stay tuned. Many thanks!~
-
【Product for Licensing】ANTI-CDCP1 mAb and ADC
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. We will discuss with you and may present the non-confidential deck to you for review asap.
-
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Congratulations to Day One Biopharmaceuticals and MabCare Therapeutics!
-
ASCO Express: From “low expression” to “even lower expression”, the best-selling ADC enters the next level!
Following the FDA’s accelerated approval of Enhertu (trastuzumab deruxtecan, …
-
药明直播间|生物制药系列(六)：针对抗体偶联药物的分析能力及策略
抗体偶联药物（ADC）由单克隆抗体和小分子细胞毒素通过连接子偶联而成，通过抗体靶向作用使小分子细胞毒素作用于目标细胞，改善了治疗窗口。近十年来，ADC市场发展迅猛。药明生物旗下的分…
-
FDA授予Enhertu优先审查资格，用于治疗HER2阳性晚期胃癌
原文始发于微信公众号（药时代）：FDA授予Enhertu优先审查资格，用于治疗HER2阳性晚期胃癌 2020年10月28日，阿斯利康和第一三共制药联合宣布FDA已经受理了Enher…
-
Seagen接替Seattle Genetics，这位先驱与他的ADC药物是否即将开启新的健康篇章？
原文始发于微信公众号（药时代）：Seagen接替Seattle Genetics，这位先驱与他的ADC药物是否即将开启新的健康篇章？ ⬆️欢迎参加2020中国新药CMC高峰论坛！…
-
精准肿瘤学的未来
⬆️ 欢迎参加2020中国新药CMC高峰论坛！ 本文转自药渡，作者cageling，点击阅读原文 国际著名学术期刊《Cancer Cell》发表了题为“Toward a More …
-
ADC药物研发的关键四要素及发展趋势
⬆️ 欢迎参加2020中国NASH大会！ 本文转自药渡，作者药渡咨询郭雷团队，点击阅读原文 ADCs（antibody-drugconjugates）技术是通过linker将单抗和…
